Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Safety and performance results from PATHFINDER 2, a registrational study of a multi-cancer early detection (MCED) test in an intended-use population.

Of 287 (0.9%) participants with a positive test, 173 were diagnosed with cancer within 12 months (detection rate 0.5%; PPV 60.3%, 95% CI 54.5-65.8%; specificity 99.6%). Twelve-month episode sensitivity was 69.8% in a prespecified 12-cancer subgroup, 66.2% in 6 aggressive cancers, and 39.3% across all cancers. Cancer-signal-origin accuracy was 91.3%. Of 151 MCED-detected new primaries, 80 (53.0%) were stage I-II. Five study-related adverse events occurred during diagnostic workup; none were serious. Median time from result to diagnostic resolution was 48 days.

ASCO Annual Meeting 2026